Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan
- 446 Downloads
Objectives The primary goal of the present study was to implement and evaluate the impact of pharmaceutical care service for hospitalized chronic kidney disease (CKD) patients in Jordan. Setting Nephrology wards of one of the largest general hospitals in Jordan. Methods All patients who were previously diagnosed with CKD by their physician were eligible for inclusion in the study. Recruited patients were fully assessed for treatment related problems (TRPs) by a clinical pharmacist. Pharmaceutical care service was assessed through a systematic, prospective before–after design. Chi Square test was used to investigate association between categorical variables. P value <0.05 was considered to be statistically significant. Main outcome measures Study outcomes included: Process outcomes (prevalence and nature of identified TRPs, clinical significance of TRPs, associated diseases and drugs), General clinical outcomes (Therapeutic outcomes of TRPs) and CKD specific clinical outcomes (Change from baseline in the number of patients receiving appropriate progression modifying therapy and appropriate management of complications). Results 130 patients were included in the study. The average number of the identified TRPs was 5.31. Eighty-six percent of the recommendations were accepted by physicians. Efficacy related problems were the most common TRP category. Seventeen percent of all TRPs were resolved, 5.5 % were improved, and 37.4 % were prevented through the clinical pharmacist interventions. Conclusions The current study indicated that hospitalized patients with CKD suffer from multiple TRPs mostly related to efficacy of medications and patients monitoring. Clinical pharmacists substantially contributed towards the care of hospitalized CKD patients through optimizing progression modifying therapies, medications safety and management of CKD complications. Based on this study it is strongly recommended to implement pharmaceutical care services for hospitalized CKD patients.
KeywordsChronic kidney disease Clinical pharmacy Drug related problems Jordan Pharmaceutical care Treatment related problems
The authors wish to thank all patients, pharmacists and physicians who contributed to the success of this work.
Conflicts of interest
The Authors declare that they have no conflicts of interest to disclose.
- 1.Canadian Institute for Health Information. Dialysis and Renal Transplantation. Canadian Replacement Register; 2001. http://www.cihi.ca/cihi-ext-portal/internet/en/document/types+of+care/specialized+services/organ+replacements/services_corr?
- 17.Cipolle R, Strand L, Morley P. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004. ISBN: 978-0071362597.Google Scholar
- 18.Aburuz S. The case for evidence based pharmaceutical care. Res Social Adm Pharm 2009: [Epub ahead of print].Google Scholar
- 22.Desrochers JF, Lemieux JP, Morin-Belanger C, Paradis FS, Lord A, Bell R, et al. Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. Am J Kidney Dis. 2011;58:527–35.Google Scholar